HOUSE lead prosecutor Gerville “Jinky Bitrics” Luistro of Batangas on Friday said Vice President Sara Z. Duterte’s defense panel continued answering questions about business registration while leaving the prosecution’s P818-million unexplained-wealth allegation under Article II unanswered.
The lawmaker said that the testimony establishing Cale88’s registration did not address the financial evidence presented against Duterte.
“Ang sabi ng ibang kasamahan natin, hindi pa tumatama ang suntok,” Luistro said, repeating her colleagues’ assessment of the defense presentation.
DTI Undersecretary Dr. Ceferino Rodolfo testified on Cale88’s Board of Investments records.
FDA official Pilar Marilyn Pagayunan discussed product registrations and the documents supporting them.
Luistro said those subjects did not reach the financial questions the defense needed to address.
“Mukhang nililihis po ang issue,” she said. “Maliwanag po ang specific allegations ng prosecution.”
House prosecution spokesperson Ace Barbers likewise said the latest witnesses have yet to rebut the prosecution’s evidence.
He acknowledged Rodolfo confirmed the company’s registration but questioned what this established about the alleged unexplained wealth.
Luistro drew a distinction between a witness’ professional standing and the relevance of the testimony offered.
She said the defense had the prerogative to choose its witnesses and therefore controlled the subjects it brought before the court.
“They are not completely relevant because it does not answer the fact in issue,” she said.
She asked for testimony explaining the financial records behind the prosecution’s allegations of unexplained wealth and undeclared assets.
“So I think it’s not the quality of the witness, but it is the nature of the testimony,” Luistro said.
Today’s hearing saw prosecutors accepting registration matters by stipulation, or agreement about facts and records.
In the FDA presentation, the agreed matters included two product registrations, one for local manufacture and another for export, and compliance with the requirements supporting their issuance.
Luistro said prosecutors were free to conduct or forgo cross-examination. Even testimony outside the central issue, she said, offered opportunities to obtain admissions and establish inconsistencies.
“At the very least nakakakuha ng admission, nakaka-establish ng inconsistency,” she said.
“Will the BOI registration answer that issue? No. Will the FDA registration answer that issue? No,” she added
metrosundaily